Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06510322 · ClinicalTrials.gov registry record · Early Phase 1
Sildenafil to Reduce Vascular Remodeling During Left Ventricular Assist Device Support
A Early Phase 1 study of Vascular Diseases, sponsored by Montefiore Medical Center.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT06510322 is a Early Phase 1 study of Vascular Diseases that is actively recruiting participants, run by Montefiore Medical Center. The registered enrollment target is 50 participants, below the 560-participant average among 40 other Vascular Diseases trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06510322, a Early Phase 1 study of Vascular Diseases, is actively recruiting participants, sponsored by Montefiore Medical Center.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
Contemporary left ventricular assist device (LVAD) therapy improves survival during advanced heart failure but vascular aging develops rapidly leading to major adverse events including stroke and bleeding in nearly half of patients. In this study, the study team aims to investigate whether sildenafil pharmacotherapy, which has anti-fibrotic effects, can reduce vascular aging during LVAD support. An aim of this study is to compare changes in small blood vessels in the gastrointestinal tract between participants receiving sildenafil or placebo. Video capsule endoscopy (VCE) will be used to assess these changes in small blood vessels.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Sildenafil
Study Locations (1)
New York
- Montefiore Medical Center - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-03-12 |
| Est. Completion | 2029-12 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06510322
The ClinicalTrials.gov registry entry for NCT06510322 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 560-participant average among 40 other Vascular Diseases trials with a reported enrollment target (91% lower). The listed sponsor is Montefiore Medical Center, which has 345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Vascular Diseases appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06510322 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT06510322 about?
NCT06510322 is a clinical study titled "Sildenafil to Reduce Vascular Remodeling During Left Ventricular Assist Device Support". Contemporary left ventricular assist device (LVAD) therapy improves survival during advanced heart failure but vascular aging develops rapidly leading to major adverse events including stroke and bleeding in nearly half of patients. In this study, the study team aims to investigate whether sildenafi...
What is the current status of trial NCT06510322?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 50 participants. The study started on 2025-03-12. Estimated completion is 2029-12.
What conditions does trial NCT06510322 study?
This clinical trial studies the following conditions: Vascular Diseases.
What interventions are being tested in trial NCT06510322?
The interventions under investigation include: Placebo (OTHER), Sildenafil (DRUG).
Who is sponsoring clinical trial NCT06510322?
This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06510322 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Vascular Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Eliminating Severe Maternal Morbidity With Heart Health Doulas Trial
RECRUITING · NA
-
Treatment With Aspirin After Preeclampsia: TAP Trial
RECRUITING · Phase 4
-
Factors Affect Outcomes in Cardiovascular Surgery
RECRUITING
-
Screening for Social Determinants of Health (SDOH) and Cognitive Function in Individuals With History of Stroke
RECRUITING
-
Natural History of Stroke: Cause and Development
RECRUITING
-
Efficacy and Mechanisms of Dapagliflozin in Promoting Kidney Function and Cardiovascular Health in Kidney Transplant Recipients
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.